KoBioLabs, Inc.
Financials
Valuation Metrics
KoBioLabs, Inc.'s Market Cap is ₩592B. At end of 2025 it was ₩1113B. Ranked #1618 of 2,436 in KR market (top 66%), #955 of 1,649 on KOSDAQ (top 58%), #178 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 76%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 59.23B KRW | KR#1,618/2,436 Sec#178/234 |
| Revenue | 71.21B KRW | KR#1,598/2,436 Sec#103/234 |
| Net Income | -6.97B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 90.80B KRW | KR#1,825/2,436 Sec#148/234 |
| Net Assets | 46.99B KRW | KR#1,919/2,436 Sec#167/234 |
| Employees | 57 | KR#1,967/2,436 Sec#173/234 |
| Value | ||
| P/B | 1.26x | KR#1,682/2,436 Sec#117/234 |
| P/S | 0.83x | KR#1,268/2,436 Sec#68/234 |
| FCF Yield | -10.27% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -14.84% | KR#1,989/2,436 Sec#157/234 |
| ROA | -7.68% | KR#1,995/2,436 Sec#151/234 |
| Op. Margin | -12.44% | KR#2,037/2,436 Sec#141/234 |
| Revenue Growth | 11.10% | KR#878/2,436 Sec#77/234 |
| Financial Health | ||
| Debt Ratio | 93.25% | KR#304/2,436 Sec#38/234 |
| Total Debt | 16.26B KRW | KR#1,439/2,436 Sec#124/234 |
| FCF | -6.08B KRW | KR#1,556/2,436 Sec#123/234 |
| Cash | 7.07B KRW | KR#1,857/2,436 Sec#163/234 |
| Current Ratio | 3.91x | KR#431/2,436 Sec#73/234 |
| Performance | ||
| 1Y Return | -38.57% | KR#1,802/2,436 Sec#159/234 |
| 1M Return | -9.36% | KR#1,721/2,436 Sec#173/234 |
| From 52W High | -65.06% | KR#1,957/2,436 Sec#168/234 |
| 1Y MDD | -61.69% | KR#1,505/2,436 Sec#119/234 |
| Trading | ||
| Volume | 17,057 shares | KR#1,926/2,436 Sec#191/234 |
| Foreign Own. | 2.90% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -190 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,546 KRW | KR#2,149/2,436 Sec#187/234 |
Company Info
KoBioLabs, established in 2014 and listed on KOSDAQ in 2020, is a microbiome-specialized biotech company. It develops human microbiome-based therapeutics like CUREbiotics and operates a health functional food business, producing and selling probiotic products via its subsidiary, WeBiome. Through its Smartiome 2.0 new drug development platform, the company has established a therapeutic pipeline for immune diseases and secured core competitiveness in the bio sector by commencing global clinical trials for microbiome new drugs.